Evidence map›Paper›PMID 31005862›Full record

ArticleBMJ case reports2019

MDS with 5q deletion and rare

Daniel Steven Sanders, Thomas Fennell, Mohammad Muhsin Chisti

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ case reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Daniel Steven SandersDepartment of Internal Medicine, McLaren-Oakland Hospital, Pontiac, Michigan, USA.
Thomas FennellDepartment of Pathology, Oakland University William Beaumont Hospital, Royal Oak, Michigan, USA.
Mohammad Muhsin ChistiDepartment of Hematology and Medical Oncology, Oakland University William Beaumont School of Medicine, Royal Oak, Michigan, USA.ORCID http://orcid.org/0000-0002-2676-9577
Oakland University · USMcLaren Health Care · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A patient with a diagnosis of myelodysplastic syndrome (MDS) with isolated 5q deletion underwent repeat bone marrow biopsy to assess haematological response after 6 months of initial lenalidomide therapy. Subsequent bone marrow biopsies revealed persistent MDS with del(5q) in addition to a small atypical mast cell population with >25% of mast cells with spindle-shaped morphology and immunohistochemistry characteristics consistent with mastocytosis. Molecular testing on the bone marrow was positive for

Indexed as

Anemia, MacrocyticBiopsyBone MarrowChromosome DeletionChromosomes, Human, Pair 5Hematologic NeoplasmsHumansImmunologic FactorsLenalidomideMaleMastocytosisMiddle AgedMutationMyelodysplastic SyndromesImmunologic FactorsLenalidomidehaematology (incl blood transfusion)malignant and benign haematologyoncology

Identifiers

PMID31005862
PMCPMC6506002
OpenAlexW2938143378

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.